bluebird bio News

Bluebird Bio Faces Nasdaq Compliance Challenge and Delays

TipRanksApr 26 16:23 ET

Express News | Bluebird bio Announces Receipt of Expected Notice From Nasdaq

ReutersApr 26 16:05 ET

Cerebral Adrenoleukodystrophy Pipeline Insight 2024, Featuring Key Players Minoryx Therapeutics, POXEL, Orpheris and Bluebird Bio

Yahoo FinanceApr 17 05:50 ET

Express News | Bluebird Bio Inc Anticipates It Will Be Delayed In Filing Its Quarterly Report On Form 10-Q For Q1 Of 2024

Moomoo 24/7Apr 16 16:26 ET

Express News | bluebird bio Shares Down 9% at $0.90 After the Bell Following Announcement of Delay in 10-Q Filing

Moomoo 24/7Apr 16 16:23 ET

Express News | bluebird bio Inc - Anticipates It Will Be Delayed in Filing Its Quarterly Report on Form 10-Q for the First Quarter of 2024

Moomoo 24/7Apr 16 16:08 ET

TD Cowen Says Sickle Cell Therapies May Get Higher CMS Payments

Seeking AlphaApr 15 16:46 ET

Express News | Watching Bluebird Bio; Shares Spike Higher As Traders Circulating Unconfirmed Rumor Suggesting "Lyfgenia Is Among 8 New Therapies In The Running To Receive NTAP Designations At The Start Of FY25. The Emphasis On Supporting Access For SCD Therapies Across

Moomoo 24/7Apr 15 16:17 ET

Is Bluebird Bio Stock a Buy?

The Motley FoolApr 15 08:15 ET

Better Buy: Bluebird Bio Vs. Novavax

The Motley FoolApr 13 16:22 ET

Is This Beaten-Down Stock a Good Acquisition Target?

Yahoo FinanceApr 11 08:30 ET

Bluebird Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business WireApr 11 08:00 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)

TipRanksApr 8 22:00 ET

Bluebird Bio, Inc. (NASDAQ:BLUE) Q4 2023 Earnings Call Transcript

Yahoo FinanceApr 2 11:33 ET

Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst

The Motley FoolMar 29 05:20 ET

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Bluebird Bio (BLUE)

TipRanksMar 29 04:20 ET

Peeling Back The Layers: Exploring Bluebird Bio Through Analyst Insights

During the last three months, 4 analysts shared their evaluations of bluebird bio (NASDAQ:BLUE), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent rating

BenzingaMar 27 12:01 ET

RBC Capital Reiterates Sector Perform on Bluebird Bio, Maintains $6 Price Target

RBC Capital analyst Luca Issi reiterates bluebird bio with a Sector Perform and maintains $6 price target.

Analyst UpgradesMar 27 11:36 ET

Bluebird Biotech Set to Outperform Pessimistic Expectations – Broker | NASDAQ:BLUE

Proactive InvestorsMar 27 10:50 ET

Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo

Bluebird Bio Is Maintained at Equal-Weight by Wells Fargo

Dow JonesMar 27 08:44 ET